SYNLOGIC, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount
SYNLOGIC, INC. (SYBX) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount of $9.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther · last filed 2026-03-12
- SYNLOGIC, INC. effective income tax rate reconciliation, nondeductible expense, other, amount for fiscal 2025 was $9.00K.
- SYNLOGIC, INC. effective income tax rate reconciliation, nondeductible expense, other, amount for fiscal 2017 was $307.00K, a 207.00% increase from fiscal 2016.
- SYNLOGIC, INC. effective income tax rate reconciliation, nondeductible expense, other, amount for fiscal 2016 was $100.00K.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount 12 month |
|---|---|
| 2025-12-31 | $9.00K 10-K · filed 2026-03-12 |
| 2017-12-31 | $307.00K 10-K · filed 2018-03-20 |
| 2016-12-31 | $100.00K 10-K · filed 2018-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |